Friday, February 12, 2021 10:21:20 AM
) PROCEED WITH PACE: The spin-off should be completed by year-end 2021.
In order to facilitate the spin-off of Bausch Global Eyecare as an investment grade Company, we recommend Bausch Health Companies retain a globally recognized investment banking firm to seek capital for an up to a 40% equity stake in BGE prior to its spin-off. To be clear, we are recommending raising capital by selling a stake in the eyecare subsidiary, BGE, at fair value, and we specifically recommend against selling any equity in the current holding company, BHC, whose fair value is meaningfully higher than its current share price, in our opinion. This fresh capital would allow for the creation of an investment grade BGE at inception while beginning to improve the credit ratios of the remainder of Bausch Health Companies. We believe this capital could come from a SPAC merger partner, private equity firm, leading North American or global investment institutions or the IPO market.
Recent ENZN News
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2024 09:05:44 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:31:10 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/07/2023 08:06:31 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM